Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of ruxolitinib plus novel agents such as siremadlin demonstrated promising efficacy and safety among patients with myelofibrosis who had suboptimal response to ruxolitinib monotherapy.
The combination of ruxolitinib plus novel agents such as siremadlin demonstrated promising efficacy and safety among patients with myelofibrosis who had suboptimal response to ruxolitinib monotherapy.
What percentage of patients with relapsed/refractory myelofibrosis treated with novel pan-lysyl oxidase inhibitor PXS-5505 experienced a total symptom score reduction of 20% or more in a phase 1/2a clinical trial?15.3%32%90%62%
What percentage of patients with relapsed/refractory myelofibrosis treated with novel pan-lysyl oxidase inhibitor PXS-5505 experienced a total symptom score reduction of 20% or more in a phase 1/2a clinical trial?15.3%32%90%62%
For patients with MF who are refractory to Janus kinase inhibitor treatment, novel pan-lysyl oxidase inhibitor PXS-5505 demonstrated promising safety and tolerability, according to a phase 1/2a trial.
For patients with MF who are refractory to Janus kinase inhibitor treatment, novel pan-lysyl oxidase inhibitor PXS-5505 demonstrated promising safety and tolerability, according to a phase 1/2a trial.
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
In part 1 of this expert roundtable covering the latest in myelofibrosis management and treatment, Firas El Chaer, MD, discuss updates in diagnosis and risk stratification with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 1 of this expert roundtable covering the latest in myelofibrosis management and treatment, Firas El Chaer, MD, discuss updates in diagnosis and risk stratification with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of ruxolitinib plus novel agents such as siremadlin demonstrated promising efficacy and safety among patients with myelofibrosis who had suboptimal response to ruxolitinib monotherapy.
The combination of ruxolitinib plus novel agents such as siremadlin demonstrated promising efficacy and safety among patients with myelofibrosis who had suboptimal response to ruxolitinib monotherapy.
For patients with MF who are refractory to Janus kinase inhibitor treatment, novel pan-lysyl oxidase inhibitor PXS-5505 demonstrated promising safety and tolerability, according to a phase 1/2a trial.
For patients with MF who are refractory to Janus kinase inhibitor treatment, novel pan-lysyl oxidase inhibitor PXS-5505 demonstrated promising safety and tolerability, according to a phase 1/2a trial.
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
What percentage of patients with relapsed/refractory myelofibrosis treated with novel pan-lysyl oxidase inhibitor PXS-5505 experienced a total symptom score reduction of 20% or more in a phase 1/2a clinical trial?15.3%32%90%62%
What percentage of patients with relapsed/refractory myelofibrosis treated with novel pan-lysyl oxidase inhibitor PXS-5505 experienced a total symptom score reduction of 20% or more in a phase 1/2a clinical trial?15.3%32%90%62%
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...
True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...
True or False: Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that demonstrated insight into the appropriateness of the symptom change threshold used in the phase 3...
True or False: Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that demonstrated insight into the appropriateness of the symptom change threshold used in the phase 3...
The addition of parsaclisib to stable-dose ruxolitinib treatment ___ splenomegaly and ___ symptom scores among patients with primary or secondary myelofibrosis who did not have optimal responses to ruxolitinib alone, according to findings...
The addition of parsaclisib to stable-dose ruxolitinib treatment ___ splenomegaly and ___ symptom scores among patients with primary or secondary myelofibrosis who did not have optimal responses to ruxolitinib alone, according to findings...
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of ruxolitinib plus novel agents such as siremadlin demonstrated promising efficacy and safety among patients with myelofibrosis who had suboptimal response to ruxolitinib monotherapy.
The combination of ruxolitinib plus novel agents such as siremadlin demonstrated promising efficacy and safety among patients with myelofibrosis who had suboptimal response to ruxolitinib monotherapy.
For patients with MF who are refractory to Janus kinase inhibitor treatment, novel pan-lysyl oxidase inhibitor PXS-5505 demonstrated promising safety and tolerability, according to a phase 1/2a trial.
For patients with MF who are refractory to Janus kinase inhibitor treatment, novel pan-lysyl oxidase inhibitor PXS-5505 demonstrated promising safety and tolerability, according to a phase 1/2a trial.
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...
According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...
Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.
Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
